|Articles|September 1, 2001

Pharmaceutical Executive-09-01-2001
Volume 0
Issue 0

Inefficiencies: Cutting Through the Jungle

Berlin-The German healthcare system is ailing, and politicians are too timid and inefficient to do anything about it, according to the Verband Forschender Arzneimittelhersteller (VFA), Germany’s pharmaceutical industry trade association.

Articles in this issue

about 25 years ago

Article

Profits and Promotion Under Attack

about 25 years ago

Article

New Playing Fields

about 25 years ago

Article

Legislation: EC Proposes Changes

about 25 years ago

Article

Flexing Their Budgets: Big Pharma Spend Trends

about 25 years ago

Article

Media Mix Town Meeting 2001: Much Ado About Media

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 9th, 2026

Pharmaceutical Executive Daily: FDA Approves Tecentriq

The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.

October 9th, 2026

Naoki Okamura: Post-Patent Plan and Purpose

Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.

October 9th, 2026

The Future of Precision Medicine Depends on More Than Biology

As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.

October 9th, 2026

Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing

TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.

Roche’s Tecentriq gains an adjuvant colon cancer indication tied to mismatch repair testing, with a 50% lower recurrence or death risk reported in ATOMIC. Credit: Stock.Adobe.com/Pakin

October 9th, 2026

FDA Approves Tecentriq for Stage III dMMR Colon Cancer

The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.

October 9th, 2026

The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026

Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.

October 8th, 2026

Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.

October 8th, 2026

A Steadying Trajectory: Biopharma Review and Outlook

Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.

Inefficiencies: Cutting Through the Jungle

Articles in this issue

Related to this article

Trending on PharmExec

Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing

FDA Approves Tecentriq for Stage III dMMR Colon Cancer

The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026

Viatris Acquires Pacira BioSciences for $1.65 Billion

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million